Last Updated : September 20, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Active | |||
TBC | rozanolixizumab | Generalized myasthenia gravis (gMG) | Active | |||
TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
TBC | tarlatamab | Extensive stage small cell lung cancer | Active | |||
TBC | garadacimab | Hereditary angioedema (HAE) | Active | |||
TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
TBC | belantamab mafodotin, bortezomib, dexamethasone | Previously treated multiple myeloma | Pending | |||
TBC | belantamab mafodotin, pomalidomide, dexamethasone | Previously treated multiple myeloma | Pending | |||
TBC | trofinetide | Rett syndrome (RTT) | Pending | |||
TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
TBC | donanemab | Alzheimer's disease | Active | |||
TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Active | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
TBC | delgocitinib | Chronic hand eczema | Pending | |||
TBC | momelotinib | Myelofibrosis | Active | |||
TBC | Efanesoctocog alfa | congenital factor VIII deficiency | Received | |||
TBD | iptacopan | paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
TBD | Cabozantinib | Withdrawn | ||||
TBD | Rituximab | Cancelled |